After splashing out $27.8bn for Horizon Therapeutics, Amgen is now seeing growth with drugs like Tepezza, Krystexxa, and Uplizna. Credits: Marlon Trottmann/Shutterstock.com Amgen has announced a total revenue of $8.5bn in Q3 2024, a 23% increase from a $6.9bn revenue […]
Amgen earns higher revenues in Q3 2024, puts rare diseases in the spotlight Read More »
Adbry targets interleukin-13 (IL-13), a cytokine that drives inflammatory processes that drive symptoms of atopic dermatitis. Credits: Evgeniia Primavera / Shutterstock. Leo Pharma has announced long term safety and efficacy data for its atopic dermatitis treatment, Adbry (tralokinumab-ldrm), demonstrating the
LEO’s Adbry demonstrates long-term efficacy in atopic dermatitis Read More »
The Ion Torrent Oncomine Dx Target Test is the first FDA-approved next generation sequencing-based diagnostic. Credits: JHVEPhoto / Shutterstock. Thermo Fisher Scientific has announced that its in vitro diagnostic test, Oncomine, has won US Food and Drug Administration (FDA) approval
Thermo Fisher’s Oncomine gains FDA approval as brain tumor diagnostic Read More »
The latest round of layoffs will see Sage reduce 33% of its total workforce. Credits: Wirestock Creators/Shutterstock.com After a series of mid-stage clinical trial failures, Sage Therapeutics has announced that it will jettison 165 employees, which totals 55% of its
Sage lays off 55% of R&D workforce and refocuses pipeline Read More »
Stelara is indicated for use in patients with active psoriatic arthritis as well as moderate to severe Crohn’s disease, plaque psoriasis, and active ulcerative colitis. Credits: Tada Images/Shutterstock.com South Korea-based Dong-A ST has received a US Food and Drug Administration
South Korean company Dong-A ST wins FDA approval for Stelara biosimilar Read More »
NP001 is designed to reestablish the balance of pro- and anti-inflammatory processes. Credits: David Herraez Calzada/Shutterstock.com Neuvivo has submitted a New Drug Application (NDA) for its investigational amyotrophic lateral sclerosis (ALS) immunotherapy to the US Food and Drug Administration (FDA).
Neuvivo makes bid to enter ALS arena with immunotherapy candidate Read More »
TRIV-573 is a preclinical bispecific antibody designed to target KLK5/7 and interleukin IL-13. Credits: Kmpzzz / Shutterstock. Triveni Bio has secured $115m in a Series B funding round to advance its preclinical antibody candidates for immunological and inflammatory diseases. The
Triveni scores $115m to expand immunology pipeline Read More »
COPD is the sixth approved indication for the interleukin-4 receptor alpha antagonist monoclonal antibody. Credits: Wildflower_macro/Shutterstock.com With the latest nod from the US Food and Drug Administration (FDA), Regeneron Pharmaceuticals and Sanofi have expanded the US label of Dupixent (dupilumab)
FDA greenlights Regeneron’s Dupixent for the treatment of COPD Read More »
